Shots: The US FDA approved Udenyca Onbody earlier in Dec 2023, as an OBI device to administer Udenyca, a biosimilar of pegfilgrastim. The company has launched Udenyca in the US market for the treatment of patients with non-myeloid malignancies Udencya is a leukocyte growth factor indicated to be administered the day after CT to lower the rate…
